Related Experiment Video
Updated: Dec 12, 2025
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Time interval from biopsy to surgery and risk for adjuvant therapy in patients with low-risk endometrial cancer
Yfat Kadan1, Aula Asali2, Ami Fishman2
1Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Meir Medical Center, Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Center. Affiliated with the Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Objective:
Among patients with endometrial cancer, longer wait times to surgery were associated with decreased survival. Although endometrial cancer survival rate is high, about 45% of patients receive adjuvant therapy. The aim of this study was to examine whether a longer interval from diagnosis to surgery is associated with increased need for adjuvant treatment among patients with low-risk endometrial cancer.
Methods:
A retrospective cohort study of endometrioid endometrial cancer patients treated with surgery between the years 1999 and 2013 was conducted. Patients with pre-operative histology of hyperplasia, grade 1/2 cancers were included. Patients with stage IV disease were excluded. Demographic, clinicopathologic and surgical parameters were collected and correlation with wait time was evaluated. The risk for adjuvant therapy was in two-week intervals from biopsy to hysterectomy.
Results:
468 patients were included in the final cohort. 84.3% had stage I disease and 43.8% patients received adjuvant treatment. Mean time from diagnosis to surgery was 63.88 days (SD 10.3, 31-94). The risk for adjuvant therapy was not increased at any of the time intervals that were examined.
Conclusion:
In low risk endometrial cancer, longer time interval between diagnosis and surgery did not increase the need for adjuvant therapy.
